Esperion Therapeutics (ESPR) Proxy filing summary

Executive summary

• Entered into a definitive agreement to be acquired by ARCHIMED, a healthcare-focused investment firm, with the transaction expected to close in Q3 2026.

• Following the acquisition, the company will become privately held and continue advancing its Vision 2040 strategy.

• Until the transaction closes, operations will continue independently with no immediate changes for customers or partners.

• Forward-looking statements highlight potential risks, including regulatory approvals, shareholder approval, and possible disruptions.

Voting matters and shareholder proposals

• A special meeting of stockholders will be convened to vote on the proposed acquisition by ARCHIMED.

• Proxy materials will be filed with the SEC and distributed to securityholders, containing important information about the transaction.

Board of directors and corporate governance

• Directors and executive officers may be deemed participants in the proxy solicitation for the acquisition vote.

• Information on their interests and holdings will be disclosed in the proxy statement and related SEC filings.